636 related articles for article (PubMed ID: 30118633)
21. Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants.
Lalwani SK; Agarkhedkar S; Sundaram B; Mahantashetti NS; Malshe N; Agarkhedkar S; Van Der Meeren O; Mehta S; Karkada N; Han HH; Mesaros N
Hum Vaccin Immunother; 2017 Jan; 13(1):120-127. PubMed ID: 27629913
[TBL] [Abstract][Full Text] [Related]
22. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
[TBL] [Abstract][Full Text] [Related]
24. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth.
Posuwan N; Wanlapakorn N; Vongpunsawad S; Sintusek P; Leuridan E; Van Damme P; Poovorawan Y
Vaccine; 2020 Feb; 38(7):1643-1651. PubMed ID: 31948817
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.
Zanetti AR; Romanò L; Giambi C; Pavan A; Carnelli V; Baitelli G; Malchiodi G; Valerio E; Barale A; Marchisio MA; Montù D; Tozzi AE; D'Ancona F;
Lancet Infect Dis; 2010 Nov; 10(11):755-61. PubMed ID: 20884297
[TBL] [Abstract][Full Text] [Related]
26. Disparate kinetics in immune response of two different
Martinón-Torres F; Salamanca de la Cueva I; Horn M; Westerholt S; Bosis S; Meyer N; Cheuvart B; Virk N; Jakes RW; Duchenne M; Van den Steen P
Hum Vaccin Immunother; 2024 Dec; 20(1):2342630. PubMed ID: 38687024
[TBL] [Abstract][Full Text] [Related]
27. Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months.
Kosalaraksa P; Chokephaibulkit K; Benjaponpitak S; Pancharoen C; Chuenkitmongkol S; B'Chir S; Da Costa X; Vidor E
Hum Vaccin Immunother; 2018 May; 14(5):1257-1265. PubMed ID: 29333947
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
[TBL] [Abstract][Full Text] [Related]
29. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib.
Zinke M; Disselhoff J; ; Gartner B; Jacquet JM
Hum Vaccin; 2010 Feb; 6(2):189-93. PubMed ID: 20009522
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants.
Shao PL; Lu CY; Hsieh YC; Bock HL; Huang LM;
J Formos Med Assoc; 2011 Jun; 110(6):415-22. PubMed ID: 21741011
[TBL] [Abstract][Full Text] [Related]
31. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
[TBL] [Abstract][Full Text] [Related]
32. Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy.
Zanetti A; Desole MG; Romanò L; d'Alessandro A; Conversano M; Ferrera G; Panico MG; Tomasi A; Zoppi G; Zuliani M; Thomas S; Soubeyrand B; Eymin C; Lockhart S
Vaccine; 2017 Jul; 35(32):4034-4040. PubMed ID: 28624307
[TBL] [Abstract][Full Text] [Related]
33. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
Bar-On ES; Goldberg E; Hellmann S; Leibovici L
Cochrane Database Syst Rev; 2012 Apr; (4):CD005530. PubMed ID: 22513932
[TBL] [Abstract][Full Text] [Related]
34. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
Lim FS; Phua KB; Lee BW; Quak SH; Teoh YL; Ramakrishnan G; Han HH; Van Der Meeren O; Jacquets JM; Bock HL
Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):138-47. PubMed ID: 21323176
[TBL] [Abstract][Full Text] [Related]
35. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Tregnaghi M; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
[TBL] [Abstract][Full Text] [Related]
36. Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants.
Li Y; Li RC; Ye Q; Li C; Liu YP; Ma X; Li Y; Zhao H; Chen X; Assudani D; Karkada N; Han HH; Van Der Meeren O; Mesaros N
Hum Vaccin Immunother; 2017 Mar; 13(3):588-598. PubMed ID: 27768515
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and reactogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type B.
Shao PL; Lu CY; Hsieh YC; ; Bock HL; Huang LM
J Formos Med Assoc; 2011 May; 110(5):336-41. PubMed ID: 21621155
[TBL] [Abstract][Full Text] [Related]
38. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
Dolhain J; Janssens W; Sohn WY; Dindore V; Mukherjee P
Expert Rev Vaccines; 2019 Sep; 18(9):921-933. PubMed ID: 31328999
[No Abstract] [Full Text] [Related]
39. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine.
Tichmann-Schumann I; Soemantri P; Behre U; Disselhoff J; Mahler H; Maechler G; Sänger R; Jacquet JM; Schuerman L
Pediatr Infect Dis J; 2005 Jan; 24(1):70-7. PubMed ID: 15665713
[TBL] [Abstract][Full Text] [Related]
40. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
